Molbio Diagnostics appoints Dr Balram Bhargava and Dr Arun Kumar Jha as Independent Directors

Molbio Diagnostics, based in Goa, has announced the appointment of two new Independent Directors, Professor (Dr) Balram Bhargava and Dr Arun Kumar Jha, to its board. These additions reflect the company’s focus on enhancing healthcare accessibility through diagnostic innovations.

Professor (Dr) Balram Bhargava brings over 35 years of experience in medical research and public health. His previous roles include Director-General of the Indian Council of Medical Research and Secretary of India’s Department of Health Research. He has led efforts in managing public health crises and contributed to pandemic preparedness and health policy.

“I am honoured to join the board of Molbio Diagnostics, a company that is at the forefront of diagnostic innovation and global health impact. The opportunity to contribute to Molbio’s mission aligns perfectly with my lifelong commitment to enhancing health through affordable and accessible healthcare solutions. I look forward to bringing my experience in medical research and health policy to further Molbio’s efforts in revolutionising point-of-care diagnostics and advancing global healthcare standards,” said Professor (Dr) Bhargava.

Dr Arun Kumar Jha, with a background in public health and policy, has served as an Adviser in the Department of Economic Affairs and Economic Adviser in the Department of Health & Family Welfare, Ministry of Health & Family Welfare. He is currently the Chancellor of the National Institute of Advanced Manufacturing Technology and Senior Adviser at John Snow India. Dr Jha’s involvement in tuberculosis elimination programs, including a recent assignment with the Stop TB Partnership and the United Nations Office for Project Services (UNOPS), positions him as a key contributor to Molbio’s mission.

“Joining Molbio Diagnostics as an Independent Director is a significant step in my continued advocacy for public health and policy reform. With Molbio’s innovative Truenat platform, I see a tremendous potential to bridge healthcare gaps and improve disease management worldwide,” Dr Jha stated. “Looking forward to being part of this transformative journey and supporting Molbio’s strategic vision in making a lasting impact on global health, particularly in underserved regions.”

Commenting on the appointments, Sriram Natarajan, Director and CEO of Molbio Diagnostics, said, “These appointments reflect Molbio Diagnostics’ commitment to bringing on board leaders who are at the forefront of healthcare innovation and public health policy. Dr Jha and Dr Bhargava’s impressive backgrounds and shared dedication to improving healthcare access align perfectly with our vision of transforming global health landscapes.”

Molbio Diagnostics continues its mission to enhance healthcare accessibility with innovative diagnostic solutions. The inclusion of Dr Jha and Dr Bhargava is expected to further the company’s efforts in addressing global healthcare challenges.